104 results about "Antiparasitic agent" patented technology

In particular this invention provides for spot-on compositions for the treatment or prophylaxis of parasite infestations in mammals or birds which comprise:

• • (1) a composition comprising
    • (A) an effective amount of a 1-phenylpyrazole derivative; and/or
    • (B) an effective amount of a macrocyclic lactone antihelmintic or antiparasitic agent;
  • (2) an acceptable liquid carrier vehicle; and
  • (3) optionally, a crystallization inhibitor.

The invention also provides for a method of treating parasitic infestations or for the prophylaxis of parasite infestations in mammals or birds which comprises topically applying to said mammal treating parasitic infestations or for the prophylaxis of parasite infestations in mammals or birds which comprises topically applying to said mammal or bird an effective amount of a composition according to the present invention.

Compounds of formula (I) are used in combination with a second antiparasitic agent for the treatment of parasitic infestations in a host animal.

Compounds of formula (I) are used in combination with a second antiparasitic agent for the treatment of parasitic infestations in a host animal.

The invention recites spirocyclic isoxazoline derivatives of Formula (V.1), Formula (V.2), Formula (V.1.1), and Formula (1) stereoisomers thereof, veterinarily acceptable salts thereof, compositions thereof, processes for making, and their use as a parasiticide in an animal. The variables A, V, Z, W1, W2, W3, W, Y, X, R1a, R1b, R1c, R2, R3, R4, n, and --- are as described herein.

Biologically-active, water soluble, 3-substituted trioxanes of the formula wherein R represents a COOH- substituted aryl group, a substituted or unsubstituted heteroaryl group or an alkyl group, and C12-(p-carboxy)benzyloxy trioxanes of formula wherein R represents a substituted or unsubstituted alkyl, alkenyl, aryl or heteroaryl group and methods for their use as antiparasitic agents, particularly for the treatment of malaria.

The present invention relates to a pharmaceutical composition. The pharmaceutical composition comprises: at least one first therapeutically-active substance which is selected from carveol, thymol, eugenol, borneol, carvacrol and the isomers, derivatives and mixtures thereof; and at least one second therapeutically-active substance which is selected from an antiviral agent, an antitumour agent and an antiparasitic agent.

The invention belongs to the technical fields of antiparasitic drugs for animals, and preparation methods thereof, and concretely relates to a suspension containing albendazole, and a preparation method thereof. The above preparation comprises an albendazole bulk drug, a suspending aid, a wetting agent, an antiseptic and a flocculating agent. The suspension containing albendazole is prepared through a dispersion process, and is an off-white sticky water suspension. The suspension containing albendazole developed in the invention has the advantages of good stability, good palatability, long elimination half life, and high bioavailability, and can be used by animals as an oral preparation.

The present invention is directed to stabilized compositions comprising at least one macrocyclic lactone, or derivative thereof, in combination with levamisole, and an amino sugar stabilizing agent, optionally an additional antiparasitic agent, and a method for treating or controlling a parasitic infection or infestation in an animal by administering said composition.

Filarial parasites Brugia, Wuchereria, Loa Loa and Onchocerca cause over 20 million infections worldwide and pose a significant social and economic burden in endemic areas. The invention provides compositions and methods to treat parasitic infections in animals and plants, and to kill and inhibit the replication of parasites in infected hosts. The methods can include administering to a host in need of treatment an effective antiparasitic amount of a composition comprising biodegradable polyanhydride microparticles or nanoparticles that encapsulate antiparasitic agents, optionally in combination with antibacterial agents. Through co-encapsulation of antiparasitic and antibacterial agents into the particles, the invention provides the ability to effectively kill parasitic helminthes, worms, and flukes, with up to a 40-fold reduction in the amount of drug used. The results described herein demonstrate the effectiveness of the drug carriers to reduce both the course of treatment and the amount of drug needed to treat parasitic infections.

The invention belongs to the technical field of veterinary anti-parasitic medicaments, particularly relates to a compound ivermectin injection and a preparation method thereof, and aims to provide an injection for treating parasitic infection of livestock, expanding an anti-parasitic spectrum and enhancing a therapeutic effect and a preparation method thereof. Every 100ml of compound ivermectin injection comprises 0.5-2g of ivermectin, 2.5-10g of albendazole sulfoxide, 5-15ml of polyethylene glycol 400 (PEG400), 1-10ml of acetic ether, 0.5-2ml of benzyl alcohol, 0.05-0.2ml of alpha-thioglycerol, 10-30ml of dimethyl sulfoxide and the balance of propylene glycol. In the injection, the ivermectin and the albendazole sulfoxide are used as anti-parasitic main components; the injection has double complementary advantages; the anti-parasitic spectrum is expanded; the drug resistance probability of parasites can be effectively reduced; and the sensitivity of the parasites is improved. The invention brings a completely new situation for safely, effectively and conveniently preventing and treating parasitic diseases in animal husbandry and aquaculture of China.

The invention discloses a method for preparing a Sarah rhzomorph nano emulsion medicine composition and a formula. The preparation is an O/W (oil-in-water type) nano emulsion system which consists of ethylis oleas, Tween-80, n-butyl alcohol, ultrapure water and Sarah rhzomorph; the nano emulsion system has high medicine loading quantity (more than 11 percent); the medicine can be diluted by injection water or normal saline according to any rate in accordance with the clinical practical requirements; and the medicine is stably placed, so that the bioavailability of the medicine is greatly improved, the high dosage of the traditional transdermal medicine is effectively overcome; the insecticidal insect repellent function on the Sarah rhzomorph is greatly improved; and the clinical dosage of the Sarah rhzomorph is reduced to an extreme limit. The content of 1 percent of the preparation auxiliary materials (ethylis oleas, Tween-80, n-butyl alcohol and the like) is reduced to 4.1 percent on year-on-year basis; the content of 1 millesimal of the preparation auxiliary materials is reduced to 4.1 millesimal; the external properties are the same as those of true solution; compared with the transdermal preparation, the clinical dosage of the Sarah rhzomorph is reduced from 6mg/kg to 0.2mg/kg, and the curative effect is same; and therefore, at the present of deficiency of raw material medicines, the Sarah rhzomorph nano emulsion medicine is successfully researched, so that the dosage quantity is reduced, the dosage cost of a livestock master is reduced, the damage of the medicines to environment and public hygiene is greatly reduced; and in addition, according to an acute toxicity test and clinical pharmacodynamic test on mice, the nano emulsion medicine is free of toxic and side effects, so that the nano-level anti-parasitic medicine is safe, reliable and effective.

The invention discloses an anti-parasitical medicine in situ setting slow release injection and a preparation method thereof. The injection comprises the following components in ratio: 1-80g of an anti-parasitic disease medicine, 1-100g of a biodegradable high polymer material, 2-300mL of a dispersion medium and 0-50g of a solubilizer, wherein the content of the anti-parasitic disease medicine is1-800mg/mL. The injection can maintain long-term control effect when being medicated to a medicated object only once, the medicated object is protected from being infected by pathogens, propagation ofparasitic diseases can be economically and effectively controlled, material safety is high, prescription of a commercially available anti-parasitic disease medicine is simplified, compliance of the medicated object is improved, and control cost is reduced. Meanwhile, subcutaneous injection slow release injection is prepared by innovatively using a molluscicide, namely niclosamide, of the WHO, andthe effect of preventing schistosoma japonicum infection is achieved. The anti-parasitical medicine in situ setting slow release injection is simple in the preparation method, has good stability andis easy to use and popularize.

The invention provides a tert-butoxycarbonyl dihydroartemisine, which is characterized by that said invention provides its structural formula, and it is made up by using dihydroartemisine as initiation raw material, and making it and double tertiary butyl dicarbonate implement acidation reactino in organic solvent. The invented mecicine composition for resisting parasitic disease contains tert-butoxycarbonyl dihydroartemisine with therapeutic effective dose and pharmaceutically-acceptable carrier. Said invented product is high in therapeutical effect and low in toxicity, can be used for preventing and curing the parasitic diseases of schistosomiasis and malaria, etc.

The invention relates to a veterinary anti-parasitic injection containing carnauba wax. The preparation is mainly prepared from anti-parasitic medicine, the carnauba wax and an oily medium, wherein the anti-parasitic medicine is avermectins, praziquantel and oxfendazole; the oily medium is vegetable oil, ethyl oleate or benzyl benzoate, and more than one of the vegetable oil, ethyl oleate or benzyl benzoate can be combined to use. Glycerol mono-oleate can be added in the preparation, the carnauba wax and the glycerol mono-oleate are compositely applied, and the slow-release effect of the preparation is better. The selected preparation is prepared from 36-80 g of abamectin anti-parasitic medicine, 10-70 g of the carnauba wax, 80-120 g of the glycerol mono-oleate, 0.1-0.3 g of an antioxidant, 10-20 g of benzyl alcohol and the balance of the oily medium (per 1000ml).

The invention relates to an anti-parasitic orally disintegrating tablet for dogs and cats and a preparation method thereof and belongs to the field of veterinary preparations. The formula of the anti-parasitic orally disintegrating tablet provided by the invention comprises the following components in parts by weight: 0.1-2 parts of ivermectin, 30-60 parts of albendazole, 20-30 parts of disintegrant, 15-40 parts of filler, 1-2 parts of lubricant, 1-5 parts of glidant, 1-4 parts of surfactant and 1-4 parts of flavoring agent. The ivermectin and the albendazole are matched to prepare the orally disintegrating tablet, and the anti-parasitic orally disintegrating tablet has the advantages of simple production process, stable dosage and high production efficiency; and simultaneously, the flavoring agent is added into the orally disintegrating tablet, so that the taste of the medicament is improved, the medicament has the beef flavor, the palatability is increased, the compliance in medicament delivery of the dogs and the cats is further improved, and the anti-parasitic orally disintegrating tablet further has the advantages of more convenience in administration, fast disintegration after entering the mouth, higher bioavailability, good insect-dispelling effect in clinical use and broad application prospects.

The invention provides a dog and cat dropping pill preparation containing a feed attractant and treatment drugs (anti-parasite drugs, antibacterial drugs, non-steroidal anti-inflammatory drugs). The dropping pill preparation has excellent feeding attraction effect. In the dropping pill preparation, the feed attractant accounts for 5-55% of the weight of the dropping pill, the treatment drugs account for 0.1-35% of the weight of the dropping pill, and the matrix content at least accounts for 10% of the weight of the dropping pill. The treatment drugs contained in dropping pill can be combined with a capsule wall material and prepared into a microcapsule, and exist in the dropping pill in a microcapsule state. The capsule wall material for preparation of the microcapsule is selected from at least one of polyvinylpyrrolidone, acrylic resin, gelatin and Arabic gum. The feed attractant composing the dropping pill includes at least one of mutton tallow, mutton tallow residue, beef tallow, beef tallow residue, pork liver powder, chicken liver powder, fish meal, beef powder, chicken powder, natural bacon baking powder, and ham baking powder.

This invention relates to pharmaceutical and veterinary formulations providing enhanced solvency and stability for pharmaceutical and veterinary agents for administration to animals, especially ruminants. In addition, the invention relates to pour-on formulations for combating parasites in animals, such as cattle and sheep. In some embodiments, this invention provides glycol-ether-based pour-on formulations comprising a composition comprising a flukicide, such as, for example, clorsulon (4-amino-6-trichloroethenyl-1,3-benzene disulfonamide) and/or a macrolide anthelmintic or antiparasitic agent. In other embodiments, the invention provides pour-on formulations comprising at least one active agent, a glycol ether, and a stability enhancer. This invention also provides for methods for eradicating, controlling, and/or preventing parasite infestation in animals, such as cattle and sheep.

The invention discloses a tick cystatin. The tick cystatin is a Rhipicephalus haemaphysaloide cystatin Rhcyst-2. The invention also discloses a Rhipicephalus haemaphysaloide cystatin Rhcyst-2 gene. The Rhipicephalus haemaphysaloide cystatin Rhcyst-1 gene includes a nucleotide sequence coding an amino acid sequence represented by SEQ ID NO.1. The Rhipicephalus haemaphysaloide cystatin Rhcyst-2 has substantial cysteine protease inhibition activity and toxoplasma infection resistance, and is suitable for preparing anti-parasitical medicines.

The invention discloses an ivermectin nanoemulsion antiparasitic medicine and a preparation method thereof. A particle size range of the nanoemulsion is 1-100nm and the nanoemulsion comprises the following raw materials in percentage by mass: 0.10-1.00% of ivermectin, 1.00-20.00% of cosurfactant, 10.00-20.00% of surfactant, 1.00-5.00% of oil phase and the balance being distilled water. The nanoemulsion disclosed by the invention is a colorless, clear and transparent liquid in appearance, and has characteristics of low viscosity, good stability, strong dispersion, high absorption speed and targeted medicine release; in addition, the dissolubility and bioavailability of the medicines are improved and toxic and side effects are reduced. The nanoemulsion can take a good expelling and killing effect on in vitro and vivo parasites, particularly on nematode and arthropod, and can effectively prevent and treat parasitic diseases of animals within a wide spectrum.

The invention belongs to the technical fields of antiparasitic agents for animals, and preparation methods thereof, and concretely relates to an atipamezole hydrochloride-containing calming and pain easing tablet for pets, and a preparation method thereof. The above preparation comprises an atipamezole hydrochloride raw drug, an adhesive, a wetting agent, a disintegrating agent, a filler and a sweetener. The atipamezole hydrochloride-containing tablet is prepared through a wet process, and is an off-white tablet. The atipamezole hydrochloride-containing tablet has good stability and good palatability, and can be used as an oral preparation for animals.

The invention discloses a niclofolan-contained compound sustained-release animal parasiticide, aiming at solving the problems of parasitic mixed infection or multiple infection of the livestock and the poultryin the livestock and poultry cultivation. The niclofolan-contained compound sustained-release animal parasiticide comprises the following raw materials by weight percent: 10-50 percent of niclofolan, 3-20 percent of parasite repellent, 10-40 percent of sustained-release matrix material, and the balance of adhesive. The parasite repellent is one of the ivermectin, the avermectins and the albendazole; the sustained-release matrix material is the hydroxypropyl methyl cellulose; and the adhesive is polyvinylpyrrolidone. The niclofolan-contained compound sustained-release animal parasiticide has broad spectrum and good sustained-release effect, can repel different age groups of various parasite larvae parasitized on the livestock and the poultry by over 97.5 percent, is convenient to use and saves the animal treatment cost. The niclofolan-contained compound sustained-release animal parasiticide can prevent the livestock and the poultry against spring weakness death and weight losscaused by the parasites, thereby being an ideal medicament of preventing the livestock and the poultry like the cattle and the sheep against the parasites.